Stifel raised the firm’s price target on Johnson & Johnson to $170 from $160 and keeps a Hold rating on the shares. Helped by better-than-expected Q3 Pharmaceutical division performance, both Johnson & Johnson Q3 sales and EPS outperformed Stifel and consensus, the firm notes. And looking ahead, the company’s initial 2025 commentary suggests that business fundamentals are “steady-as-she-goes.” Still, looking at the company’s valuation, Stifel believes shares appear fairly valued.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Big banks, UnitedHealth report quarterly earnings: Morning Buzz
- Unusually active option classes on open October 15th
- Johnson & Johnson says China will continue to be ‘important part’ of portfolio
- Johnson & Johnson says continues to invest in R&D at ‘competitive levels’
- Morning Movers: Banks trending upward following quarterly results
Questions or Comments about the article? Write to editor@tipranks.com